Literature DB >> 21947294

Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.

Rosa Laura E van Loon1, Marcus T R Roofthooft, Hans L Hillege, Arend D J ten Harkel, Magdalena van Osch-Gevers, Tammo Delhaas, Livia Kapusta, Jan L M Strengers, Lukas Rammeloo, Sally-Ann B Clur, Barbara J M Mulder, Rolf M F Berger.   

Abstract

BACKGROUND: Incidence and prevalence rates for pediatric pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are unknown. This study describes the nationwide epidemiological features of pediatric PH in the Netherlands during a 15-year period and the clinical course of pediatric PAH. METHODS AND
RESULTS: Two registries were used to retrospectively identify children (0-17 years) with PH. Overall, 3263 pediatric patients were identified with PH due to left heart disease (n=160; 5%), lung disease/hypoxemia (n=253; 8%), thromboembolic disease (n=5; <1%), and transient (n=2691; 82%) and progressive (n=154; 5%) PAH. Transient PAH included persistent PH of the newborn and children with congenital heart defects (CHD) and systemic-to-pulmonary shunt, in whom PAH resolved after successful shunt correction. Progressive PAH mainly included idiopathic PAH (n=36; iPAH) and PAH associated with CHD (n=111; PAH-CHD). Pulmonary arterial hypertension associated with CHD represented highly heterogeneous subgroups. Syndromes were frequently present, especially in progressive PAH (n=60; 39%). Survival for PAH-CHD varied depending on the subgroups, some showing better and others showing worse survival than for iPAH. Survival of children with Eisenmenger syndrome appeared worse than reported in adults. For iPAH and PAH-CHD, annual incidence and point prevalence averaged, respectively, 0.7 and 4.4 (iPAH) and 2.2 and 15.6 (PAH-CHD) cases per million children. Compared to studies in adults, iPAH occurred less whereas PAH-CHD occurred more frequently.
CONCLUSIONS: Pediatric PH is characterized by various age-specific diagnoses, the majority of which comprise transient forms of PAH. Incidence of pediatric iPAH is lower whereas incidence of pediatric PAH-CHD is higher than reported in adults. Pediatric PAH-CHD represents a heterogeneous group with highly variable clinical courses.

Entities:  

Mesh:

Year:  2011        PMID: 21947294     DOI: 10.1161/CIRCULATIONAHA.110.969584

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  85 in total

Review 1.  Advances in pediatric pulmonary arterial hypertension.

Authors:  Dunbar Ivy
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

2.  Pulmonary Hypertension in Children - a Practical Approach.

Authors:  Eliza Cinteza; Alin Nicolescu; Cristina Filip; Andrei Lupu; Georgiana Nicolae; Gabriela Duica; Mihaela Balgradean
Journal:  Maedica (Buchar)       Date:  2015-09

Review 3.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

4.  Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension.

Authors:  Mei-Sing Ong; Mary P Mullen; Eric D Austin; Peter Szolovits; Marc D Natter; Alon Geva; Tianxi Cai; Sek Won Kong; Kenneth D Mandl
Journal:  Circ Res       Date:  2017-06-13       Impact factor: 17.367

Review 5.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

6.  Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.

Authors:  Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-01-27

Review 7.  Transthoracic echocardiography in the evaluation of pediatric pulmonary hypertension and ventricular dysfunction.

Authors:  Martin Koestenberger; Mark K Friedberg; Eirik Nestaas; Ina Michel-Behnke; Georg Hansmann
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 8.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-07

9.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  J Am Coll Cardiol       Date:  2017-06-29       Impact factor: 24.094

10.  Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension.

Authors:  Pei-Ni Jone; Julie Hinzman; Brandie D Wagner; David Dunbar Ivy; Adel Younoszai
Journal:  J Am Soc Echocardiogr       Date:  2013-12-08       Impact factor: 5.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.